adamantane has been researched along with Atherosclerotic Parkinsonism in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bassani, TB; Souza, LC; Turnes, JM; Vital, MABF | 1 |
| Kapitsa, IG; Kokshenev, II; Nerobkova, LN; Val'dman, EA; Voronina, TA | 1 |
| Abdelsalam, RM; Safar, MM | 1 |
| Kapitsa, IG; Kovalev, GI; Voronina, TA; Zimin, IA | 1 |
| Kovalev, GI; Salimov, RM | 1 |
| Ivanova, EA; Kapitsa, IG; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 1 |
| Britton, DR; DeNinno, MP; Jenner, P; Kebabian, JW; Perner, R; Schoenleber, R; Smith, L; Williams, M | 1 |
7 other study(ies) available for adamantane and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats.
Topics: Adamantane; Animals; Behavior, Animal; Dipeptides; Disease Models, Animal; Dopaminergic Neurons; Male; Memory; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats, Wistar; Treatment Outcome | 2018 |
[Effect of hemantane on bioelectric activity of brain in mice with MPTP-induced Parkinson syndrome].
Topics: Adamantane; Animals; Beta Rhythm; Male; Mice; MPTP Poisoning; Parkinson Disease, Secondary; Theta Rhythm; Time Factors | 2013 |
Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
Topics: Adamantane; Animals; Antioxidants; Apoptosis; Dopamine; Hypoglycemic Agents; Male; Motor Activity; Neuroprotective Agents; NF-E2-Related Factor 2; NF-kappa B; Nitriles; Oxidative Stress; Parkinson Disease, Secondary; Pyrrolidines; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rotenone; Signal Transduction; Uncoupling Agents; Vildagliptin | 2015 |
[Effects of subchronic hemantane administration on dopamine and serotonin receptors in intact and MPP+-treated rat brain ex vivo].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Corpus Striatum; Disease Models, Animal; Hippocampus; Male; MPTP Poisoning; Neurotoxins; Parkinson Disease; Parkinson Disease, Secondary; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D1 | 2010 |
[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Antiparkinson Agents; Disease Models, Animal; Doxycycline; Drug Combinations; Drug Synergism; Male; Maze Learning; Mice; Mice, Inbred C57BL; Motor Activity; Neurotoxins; Parkinson Disease, Secondary | 2011 |
[Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Amantadine; Animals; Antiparkinson Agents; Cognition; Drug Administration Schedule; Male; Neurotoxins; Parkinson Disease, Secondary; Rats; Time Factors | 2012 |
A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adamantane; Administration, Oral; Animals; Antiparkinson Agents; Benzazepines; Benzopyrans; Binding Sites; Callithrix; Cell Line; Dopamine Agents; Fishes; Injections, Subcutaneous; Mice; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Receptors, Dopamine D1 | 1992 |